Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
DIVERSITY in the boardrooms of the UK's largest listed companies witnessed a significant drop in the past year, a new survey has revealed.
The decline occurred due to an increased focus on hiring experienced individuals during uncertain times, found out a survey by recruitment firm Spencer Stuart.
Spencer Stuart's 2023 UK Board Index revealed a substantial decrease in the proportion of first-time appointees, women, and individuals from minority ethnic backgrounds to non-executive director positions within the top 150 boards.
The representation of minority ethnic non-executive directors dropped by 44 per cent, women by 15 per cent, and first-time appointments by 30 per cent compared to the previous year.
At the level of chief executives and chairs, the survey noted that out of the 20 chief executive appointments during the period, only three were women, and no individuals from an ethnic minority background were appointed.
In contrast, this year saw double the number of chair appointments compared to the previous year, but only four of them were women, while 18 were men. In 2022, there were six female chair appointments compared to five male chair appointments.
Chris Gaunt, head of the UK board and chief executive at Spencer Stuart, said, "These drops suggest that diversity — in terms of gender, ethnicity, and fresh perspectives — has taken a back seat as boards turn to experienced listed company directors to meet these unprecedented times head on."
Additionally, the survey revealed that the average chief executive tenure decreased by 12 per cent from 2021, reducing to 5.1 years.
Gaunt noted that this decrease represented an 'uncomfortable paradox' since the challenges faced by UK boards, such as artificial intelligence and sustainability, were growing in complexity. However, company leaders had shorter tenures to make a significant impact.
Despite the decline in overall board diversity, the data indicated a positive trend in appointing women to newer positions. With the growing prominence of environmental, social, and corporate governance boards, 78 per cent of ESG chairs were women, marking the highest proportion to date.
The report also highlighted progress in line with the FTSE Women Leaders Review and the Financial Conduct Authority's 2022 goal to achieve 40 per cent female representation on boards.
In various roles, including chair, senior independent director, chief executive, or chief financial officer, 60 per cent of boards now had at least one woman, an increase from 50 per cent in the previous year.
Gaunt emphasised the importance of diverse boards. "More diverse boards clearly offer less risk of groupthink and more nuanced, true diversity of perspective and an ability to react in a multi-layered way to complex events. This needs to be a collective societal push, with investors and executive committees expecting diversity from their boards," he pointed out.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.